TCT 2025: REC-CAGEFREE I Trial Compares Drug-Coated Balloons and Drug-Eluting Stents
The Medical Dialogues Bureau covers this news from the TCT Conference 2025 in San Francisco, USA.
The REC-CAGEFREE I trial found that drug-coated balloons (DCBs) were associated with a higher risk of device-oriented composite events (DoCE) compared with drug-eluting stents (DES) in patients with long de novo coronary artery lesions. However, outcomes were comparable for shorter lesions.
Dr. Yuehao Lv presented the findings on behalf of the REC-CAGEFREE I investigators at TCT 2025.
No direct quote available.
Author's summary: TCT 2025 presents trial results comparing DCBs and DES.
More News
- Squad Busters will shut down in 2026 after struggling to meet Supercell's expectations
- Founding partner Microsoft to bring new Discovery AI technology to NJ AI Hub
- Can IVF safe the northern white rhino from extinction? — October’s best science images
- Lululemon closes West Highland store after eight years
- Austin Reaves cracks viral joke after buzzer-beater lifts Lakers to win
- Secukinumab Looks Promising for Polymyalgia Rheumatica
- Supercell will shut down Squad Busters next year
- Danielle Smith: Balancing the budget gets a lot easier if you build a pipeline
- The real test for Sussan Ley isn’t cancel culture
- Beverage NPD: October’s top picks